Drug guide · evidence, not hype
Zepbound
tirzepatide · a dual GLP-1 and GIP receptor agonist · made by Eli Lilly
Zepbound is the weight-management brand of tirzepatide — and the first medicine FDA-approved for obstructive sleep apnea in adults with obesity. Its diabetes twin is Mounjaro: same molecule, different label.
The short answer
Zepbound is a brand name for tirzepatide, a dual GLP-1 and GIP receptor agonist made by Eli Lilly and FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. It is the same molecule as Mounjaro, which carries the type 2 diabetes indication. In the head-to-head SURMOUNT-5 trial, tirzepatide produced more weight loss than semaglutide, though that was a single open-label study.
- Molecule
- tirzepatide
- How it works
- a dual GLP-1 and GIP receptor agonist
- Maker
- Eli Lilly
- Form
- a once-weekly injection
- FDA-approved for
- chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity
- Sibling brand
- Mounjaro — the same molecule, approved for type 2 diabetes
No doses, no sourcing. This page explains what Zepbound is and points you to graded answers — it doesn’t recommend a product, a dose, or a place to buy anything.
Same molecule, different brand
Zepbound is tirzepatide. Here is how tirzepatide maps to its approved brands — Mounjaro is its sibling (the same molecule, approved for type 2 diabetes).
What each brand is approved for
| Brand | Molecule | Type 2 diabetes | Weight management | Cardiovascular risk | Obstructive sleep apnea |
|---|---|---|---|---|---|
| Zepbound | tirzepatide | — | ✓ | — | ✓ |
| Ozempic | semaglutide | ✓ | — | ✓* | — |
| Wegovy | semaglutide | — | ✓ | ✓* | — |
| Mounjaro | tirzepatide | ✓ | — | — | — |
✓ FDA-approved · ✓* approved in a defined sub-population (e.g. cardiovascular-risk reduction requires established heart disease). From each product’s FDA label. Not medical advice, not a buying guide.
Start here
The questions people actually ask about Zepbound — each answered on the site’s 8-rung Evidence Ladder and linked to primary sources.
- Rung 2Zepbound vs Wegovy: what the head-to-head evidence showsThe head-to-head with semaglutide (Wegovy).
- Rung 1Mounjaro vs. Zepbound: same molecule, two different labelsSame molecule as Mounjaro — what actually differs.
- Rung 1Tirzepatide side effects: what the evidence actually showsWhat the evidence shows about tirzepatide’s side effects.
- Rung 2GLP-1s and sleep: apnea, and the 'vivid dreams' questionThe real, FDA-approved sleep-apnea benefit — and the "vivid dreams" claim.
- Rung 1What happens when you stop GLP-1 medications?What the evidence says happens when you stop.
- Rung 3Keeping weight off after stopping a GLP-1Holding the result — the maintenance question.
Myths about Zepbound, graded
The viral claims, checked against the evidence — not a true/false binary, but how much weight the evidence can actually bear.
- Strong evidenceRung 1 of 8 · Established“Zepbound and Mounjaro are different drugs.”Same molecule — both are tirzepatide; the two brands exist because the drug is approved (and marketed) for different uses.
- Strong evidenceRung 1 of 8 · Established“Tirzepatide is just a stronger version of Ozempic.”Partly true, oversimplified
- Strong evidenceRung 2 of 8 · Supported but limited“You lose mostly muscle on GLP-1s, not fat.”Mostly false — you lose mostly fat, but some lean loss is real
- Strong evidenceRung 1 of 8 · Established“You can just stop taking it once you hit your goal weight.”Misleading overstatement
- Strong evidenceRung 1 of 8 · Established“You have to take it forever — it's a life sentence.”Mostly true on the biology, loaded in the framing — obesity is chronic, so stopping usually brings regain
Free, private tools
Everything runs on your device and stores nothing on our servers.
Sources
Every claim on this page traces to a primary source — and we sell you nothing. No sponsors, no affiliate links, no ads.
- 2 news / agency
- 1 FDA labels
- 1 randomized trials